Chronic heart failure (CHF) is a severe public health problem with increasing morbidity and
mortality, any treatment targeting a single session is insufficient to tackle this. CHF is …

Heart failure is a systemic syndrome caused by multiple pathological factors. Current
treatments do not have satisfactory outcomes. Several basic studies have revealed the …

Background: The coronary microvascular dysfunction has attracted more and more attention
in recent years, but there is still a lack of effective treatment. Shexiang Baoxin Pill is one of …

Acute myocardial infarction (AMI) has been a preclinical and clinical concern due to high
hospitalization rate and mortality. This study was aimed at evaluating the effectiveness and …

Aim: The Shexiang Baoxin Pill (SBP) has been extensively used to treat cardiovascular
diseases in China for four decades, and its clinical efficacy has been widely approved …

Background Previous studies have shown that Trimetazidine (TMZ) improves vascular
endothelial function and reduces the inflammatory process progression. However, limited …

Objectives This study was aimed to explore the mechanism of Aconiti Lateralis Radix
Praeparata (ALRP) and Zingiberis Rhizoma (ZR) on doxorubicin (DOX)-induced chronic …

Trimetazidine has been reported to benefit patients with heart failure (HF) and angina. The
impact of trimetazidine on non-ischemic HF remains unclear. We reviewed clinical trials to …

Background Recent evidence indicates that Shexiang Baoxin Pill (MUSKARDIA), as an add-
on treatment to standard therapy for stable coronary artery disease (CAD), is effective …

Promoting angiogenesis is a critical treatment strategy for ischemic cardiovascular diseases.
Shexiang Baoxin Pill (SBP), a traditional Chinese medicine, has been reported to be …